- Home
- RPAY vs ABEO Comparison
RPAY vs ABEO Comparison
Compare RPAY & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | ABEO |
|---|---|---|
| Founded | 2006 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.0M | 282.5M |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RPAY | ABEO |
|---|---|---|
| Price | $4.19 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $6.75 | ★ $15.56 |
| AVG Volume (30 Days) | 498.2K | ★ 1.9M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $309,261,000.00 | $2,998,000.00 |
| Revenue This Year | $59.55 | $693.00 |
| Revenue Next Year | $25.32 | $138.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $2.30 | $2.22 |
| 52 Week High | $4.81 | $7.65 |
Technical Indicators
Market Signals| Indicator | RPAY | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 16.34 |
| Support Level | $3.56 | N/A |
| Resistance Level | $4.68 | $5.77 |
| Average True Range (ATR) | 0.27 | 0.32 |
| MACD | -0.06 | -0.20 |
| Stochastic Oscillator | 50.70 | 2.46 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.